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ABSTRACT
Background
End-stage chronic kidney disease is associated with striking excesses of cardiovascular
mortality, but it is uncertain to what extent renal function is related to risk of subsequent
coronary heart disease (CHD) in apparently healthy adults. This study aims to quantify the
association of markers of renal function with CHD risk in essentially general populations.
Methods and Findings
Estimated glomerular filtration rate (eGFR) was calculated using standard prediction
equations based on serum creatinine measurements made in 2,007 patients diagnosed with
nonfatal myocardial infarction or coronary death during follow-up and in 3,869 people without
CHD in the Reykjavik population-based cohort of 18,569 individuals. There were small and
nonsignificant odds ratios (ORs) for CHD risk over most of the range in eGFR, except in the
lowest category of the lowest fifth (corresponding to values of ,60 ml/min/1.73m
2), in which
the OR was 1.33 (95% confidence interval 1.01–1.75) after adjustment for several established
cardiovascular risk factors. Findings from the Reykjavik study were reinforced by a meta-
analysis of six previous reports (identified in electronic and other databases) involving a total of
4,720 incident CHD cases (including Reykjavik), which yielded a combined risk ratio of 1.41
(95% confidence interval 1.19–1.68) in individuals with baseline eGFR less than 60 ml/min/
1.73m
2 compared with those with higher values.
Conclusions
Although there are no strong associations between lower-than-average eGFR and CHD risk in
apparently healthy adults over most of the range in renal function, there may be a moderate
increase in CHD risk associated with very low eGFR (i.e., renal dysfunction) in the general
population. These findings could have implications for the further understanding of CHD and
targeting cardioprotective interventions.
The Editors’ Summary of this article follows the references.
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There is a striking excess (i.e., relative risks of ’5) of
cardiovascular disease mortality in patients with end-stage
chronic kidney disease (CKD) compared with the general
population [1,2]. Strong associations have also been reported
between the occurrence of non-dialysis-dependent CKD and
subsequent incidence of cardiovascular outcomes in high-risk
groups, including patients with pre-existing ischaemic car-
diovascular diseases, heart failure, and high blood pressure
[3–7]. Major scientiﬁc societies have recommended that all
patients with manifest cardiovascular disease should be
screened for evidence of kidney disease [7]. There is, by
contrast, comparatively sparse and uncertain evidence on
renal dysfunction (evaluated using estimated glomerular
ﬁltration rate [eGFR]) and risk of cardiovascular diseases in
people without known cardiovascular or renal diseases, even
though demonstration of even modest risks in the general
population could have considerable public health and clinical
relevance. A recent systematic review identiﬁed only a few
prospective studies of non-dialysis-dependent CKD in gen-
eral populations, three of which were listed as reporting on
cardiovascular outcomes, comprising a total of only about
900 cardiovascular deaths [8]. Reports from these [9–11] (and
other more recently published [12–18]) studies have yielded
apparently conﬂicting ﬁndings, and their interpretation has
been further complicated by mixing of vascular outcomes
related to different arterial beds (such as diseases of the
coronary, cerebrovascular, and peripheral circulations).
We report new data on eGFR from the prospective
population-based Reykjavik Study of almost 19,000 middle-
aged Icelandic men and women monitored for a mean
duration of about 20 years [19]. After exclusion of partic-
ipants with evidence of baseline cardiovascular diseases or
diabetes, nested case-control analyses involved 2,007 incident
cases with either ﬁrst-ever nonfatal myocardial infarction
(MI) or coronary death and 3,869 controls, almost twice as
many CHD cases as in the previous largest population-based
report [16]. We investigated associations with a wide range of
established and emerging markers (such as those related to
lipid, inﬂammatory, ﬁbrinolytic, and metabolic pathways) in
order to better understand the correlates (and possible
determinants) of eGFR. We contextualized our new data by
conducting an updated meta-analysis of published reports on
renal function and incident CHD, involving a further 2,713
CHD cases from nine population-based prospective studies
(identiﬁed in six previous reports).
Methods
Participants
The Reykjavik Study, initiated in 1967 as a prospective
study of cardiovascular disease, has been described in detail
previously [19]. Brieﬂy, all men born between 1907 and 1934
and all women born between 1908 and 1935 who were
residents of Reykjavik, Iceland, and its adjacent communities
on 01 December 1966, were identiﬁed in the national
population register and then invited to participate in the
study during ﬁve stages of recruitment between 1967 and
1991. A total of 8,888 men and 9,681 women without a history
of myocardial infarction were enrolled, reﬂecting a response
rate of 72% percent. Nurses administered questionnaires,
made physical measurements, recorded an electrocardio-
gram, performed spirometry, and collected fasting venous
blood samples for preparation of aliquots of serum, which
were stored at 20 8C for subsequent analysis. All participants
have been monitored subsequently for cause-speciﬁc mortal-
ity and for cardiovascular morbidity, with a loss to follow-up
of only about 0.6% to date. A total of 2,007 men and women
with available serum creatinine samples and without cardi-
ovascular diseases or diabetes at baseline (i.e., participants
with self-reported diabetes or a fasting blood glucose of .7
mmol/l were excluded) had major coronary events between
the beginning of follow-up and the censoring date. Deaths
from coronary heart disease were ascertained from central
registers on the basis of a death certiﬁcate with International
Classiﬁcation of Diseases version 9 (ICD-9) codes 410–414,
and the diagnosis of nonfatal MI was based on Monitoring of
Trends and Determinants in Cardiovascular Disease (MON-
ICA) criteria [20]. We selected 3,869 controls among the
participants who had survived to the end of the study period
without having a MI, frequency-matched to cases with respect
to the calendar year of recruitment, sex, and age (in 5-y
bands). The National Bioethics Committee and the Data
Protection Authority of Iceland approved the study protocol,
and participants provided informed consent.
Estimated Glomerular Filtration Rate
Creatinine measurements were carried out within days of
the initial baseline examination (and, therefore, without
knowledge of subsequent CHD status) using Jaffe method-
ology [21]. Values of eGFR were calculated using prediction
equations involving circulating creatinine concentrations:
either the four-variable Modiﬁcation of Diet in Renal Disease
(MDRD; the principal analysis in this paper; see below) or the
Cockcroft-Gault (CG) equations (Table S1) [22,23]. Serum
creatinine is included in each formula in units of mg/dl;
eGFRCG is expressed as ml/min, whereas eGFRMDRD is
expressed as ml/min/1.73 m
2. In order to compare measure-
ment of renal function between the two methods, eGFRCG
values were standardized for body surface area using the
DuBois formula. Creatinine concentrations were also used
alone as indicators of renal function. Other analytes were
measured using standard methods, as described previously
[24]. Blood urea nitrogen levels were not available.
Statistical Analysis
Although creatinine measurements were made in all
participants at baseline, nested case-control comparisons
were used to enable analysis of data on biomarkers (e.g.
inﬂammatory and haemostatic markers) that were available
only in the nested case-control subset. Such comparisons
were made by means of unmatched logistic regression ﬁtted
according to the unconditional maximum likelihood and
progressively adjusted for possible confounding factors (Stata
version 9, http://www.stata.com/). Principal analyses were
prespeciﬁed to be by ﬁfths of values of eGFRMDRD in controls,
with further subdivision of the lowest ﬁfth into three groups
(designated 5.1, 5.2, and 5.3). Subsidiary analyses were done
using eGFRCG and creatinine levels. To facilitate comparisons
with previous studies of eGFR and cardiovascular outcomes
secondary analyses were also performed using guideline
classiﬁcation of kidney function and on the basis of eGFR
, 60 or   60 ml/min/1.73 m
2 (eGFR ,60 ml/min/1.73 m
2 is
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were based on baseline eGFR. Analyses to investigate the
shape of the eGFR-CHD association were conducted for
groups of baseline eGFR values, with corresponding 95%
conﬁdence intervals (CIs) estimated from ﬂoated variances
[26]. Subgroup analyses were prespeciﬁed by type of CHD
outcome, age, sex, smoking habits, body mass index (BMI),
systolic blood pressure, concentrations of serum lipids, blood
glucose, haemoglobin, and uric acid. Linear regression was
used to assess the association between eGFR and baseline
characteristics among controls after adjustment for estab-
lished cardiovascular risk factors (p-values for the t-statistic
from regression of GFR on each characteristic are reported).
To quantify within-person variability in levels of eGFR, that
is, the extent to which an individual’s eGFR measurements
vary around a long-term average eGFR level, regression
dilution ratios were estimated from a linear regression of the
available repeat measurements [27,28] made in samples
collected at an interval of about 12 y apart in 379 individuals,
approximately the midpoint of this study’s follow-up dura-
tion. ORs have not been corrected for regression dilution in
the present study to allow direct comparison with previous
work.
Updated Meta-analysis
A meta-analysis of prospective studies published before
March 2007 with greater than a year’s follow-up and recruited
from Western population–based sampling frameworks was
performed (Figure 1). Studies were sought using computer-
based databases (MEDLINE, EMBASE and Science Citation
Index), by scanning the reference lists of articles identiﬁed
for all relevant studies and review articles (including meta-
analyses) and hand searching of relevant journals. The
computer-based searches combined search terms related to
renal function (e.g. ‘‘creatinine’’, ‘‘glomerular ﬁltration rate’’,
‘‘kidney function’’) and coronary disease (e.g. ‘‘myocardial
infarction’’, ‘‘atherosclerosis’’, ‘‘coronary heart disease’’, and
‘‘coronary stenosis’’) without language restriction. Data were
extracted independently by two investigators, using a
prepiloted data extraction form (discrepancies were resolved
by discussion and by adjudication of a third reviewer). One
large study was not eligible for inclusion in this review
because it involved a sample of insurance screenees identiﬁed
at outpatient clinics, rather than a population-based sample
[12]. The analysis was restricted to nonfatal MI or coronary
death. Odds and hazard ratios were assumed to approximate
the same measure of relative risk. To avoid potential biases,
analyses involved only within-study comparisons (i.e., cases
and controls were only directly compared within each
cohort). We combined the results of the studies by using a
random effects model. Heterogeneity was assessed by stand-
ard v
2 tests and the I
2 statistic, which describes the percentage
of variation in the log ORs that is attributable to genuine
differences across studies rather than random error [29].
Results
The mean age at CHD event among cases in the Reykjavik
Study was about 66 y (standard deviation 8 y). As expected,
there were highly statistically signiﬁcant differences between
cases and controls with respect to established cardiovascular
risk factors (Table 1). Baseline creatinine concentrations and
eGFRMDRD showed no signiﬁcant differences between cases
and controls, whereas eGFRCG was signiﬁcantly higher in
cases than in controls (a surprising ﬁnding consistent with the
possibility of a nonlinear effect, as described below).
Baseline Associations and within-Person Variability
Values of eGFR were positively and highly signiﬁcantly
associated with male sex and smoking (p , 0.0001) and,
somewhat less signiﬁcantly, with manual occupation (p ,
0.05). After adjustment for age, sex, period of recruitment,
BMI, and smoking status there were highly signiﬁcant inverse
associations of eGFR with age, forced expiratory volume in
one second, total cholesterol, triglycerides, haemoglobin,
haematocrit, tissue plasminogen activator antigen and uric
acid (p , 0.0001) and, somewhat less signiﬁcantly, with
diastolic blood pressure, albumin, and von Willebrand factor
(p , 0.001) (Tables 2 and S2). In the participants who
provided paired measurements at baseline and about 12 y
later, the regression dilution ratios were as follows: serum
creatinine 0.64 (95% CI 0.55–0.72), eGFRMDRD 0.43 (95% CI
0.36–0.50), and eGFRCG 0.51 (95% CI 0.45–0.58). These
reproducibility values for markers of renal function were
generally similar to the values noted in the same participants
for total cholesterol 0.59 (0.51–0.67) and systolic blood
pressure 0.65 (0.54–0.77).
Renal Function and Incident Coronary Heart Disease
Age-, sex-, and time period-adjusted analyses involving
comparisons of ﬁfths of eGFR yielded weak and nonsigniﬁ-
cant ORs for CHD (Table 3), except in the lowest category of
the lowest ﬁfth of eGFRMDRD, which yielded an OR of 1.62
(95% CI 1.26–2.09), which fell to 1.33 (95% CI 1.01–1.75) after
further adjustment for several established cardiovascular risk
factors. Similar ﬁndings were observed for the same
categories of low eGFRCG and of serum creatinine concen-
tration, giving adjusted ORs of 1.24 (95% CI 0.88–1.75) and
1.40 (95% CI 1.09–1.80), respectively (Table S3). Additional
adjustment for C-reactive protein made little difference to
the adjusted ORs (see Table 3 and Table S3 legends). Figures 2
and S1 plot the adjusted ORs for CHD by ﬁfths of each of
eGFRMDRD and of eGFRCG, suggesting the possibility of a
nonlinear effect in individuals with the lowest category of
renal function (p ¼ 0.02 and p ¼ 0.002, respectively).
Subsidiary analyses using the cut point of ,60 versus  60
ml/min/1.73 m
2 in eGFR yielded similar ﬁndings (Table S4).
There was no substantial variation in the strength of
association between eGFR (comparing individuals below 60
ml/min/1.73 m
2 with those with higher values) and CHD risk
at different levels of established cardiovascular risk factors; in
particular, there were no signiﬁcant interactions (v
2 test for
interaction p . 0.05) with sex, smoking status, BMI, total
cholesterol, serum triglycerides, systolic blood pressure,
blood glucose levels, and haematocrit (either with eGFRMDRD
or eGFRCG, Figure S2). The OR may have been somewhat
higher for nonfatal MI (OR 1.75, 95% CI 1.29–2.39) than for
fatal CHD (OR 1.19, 95% CI 0.90–1.56) (p-value for difference
¼ 0.06). The ORs were largely unchanged when analyses
excluded CHD cases recorded in the ﬁrst 5 y of follow-up.
Updated Meta-analysis
We identiﬁed ten relevant prospective studies (identiﬁed in
six previous reports, plus the current study) on eGFR and
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cohorts not selected on the basis of preexisting disease) that
could be included in the present analysis because they
reported speciﬁcally on CHD outcomes (Table 4) [11,13–17].
The studies were conducted in Western Europe [14,15], the
US [11,16,17], and Australia [13]. All but one [17] involved
both men and women, all involved predominantly middle-
aged participants, all used standard creatinine assay methods
(typically the Jaffe method), all but one [14] employed
eGFRMDRD, and all adjusted risk estimates for several
established cardiovascular risk factors. Reported mean levels
(and distributions) of eGFR among these studies were similar
(Table 4). There was no clear evidence of heterogeneity
among the ﬁndings of the seven available published reports
(v
2¼12.9 with 6 df, p¼0.045; I
2¼56%, 95% CI 0%–80%), nor
was there any evidence of selective publication. Using only
within-study comparisons, a combined random effects meta-
analysis of these reports (including the present study),
involving a total of 4,720 incident CHD cases, yielded an
adjusted risk ratio of 1.41 (95% CI 1.19–1.68) in individuals
with baseline eGFR below versus those above 60 ml/min/
1.73m
2. A ﬁxed-effect meta-analysis gave a relative risk of 1.32
(95% CI 1.19–1.47, Figure 3).
Discussion
In the largest single population-based study of eGFR and
CHD to our knowledge thus far, we have shown that there are
Figure 1. Summary of Meta-Analysis Flow
doi:10.1371/journal.pmed.0040270.g001
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Renal Function and Coronary Heart DiseaseTable 1. Baseline Characteristics of Patients Who Developed CHD during the Follow-up and Controls
Category Characteristic CHD Cases Controls p-Value
n Mean (SD) or n (%) n Mean (SD) or n (%)
General Age, years 2,007 54.5 (8.6) 3,869 55.6 (9.0) Matched
Male sex 2,007 1,439 (71.7) 3,869 2,664 (68.9) Matched
Current cigarette/pipe/cigar smoker 2,007 1,218 (60.7) 3,869 1,890 (48.9) ,0.001
Current cigarette smoker 2,007 830 (41.4) 3,869 1,227 (31.7) ,0.001
Nonmanual occupation 1,463 574 (39.2) 2,819 1,196 (42.4) 0.044
BMI, kg/m
2 2,001 26.0 (4.0) 3,844 25.4 (3.7) ,0.001
Systolic blood pressure, mm Hg 2,006 146.3 (21.9) 3,852 141.3 (19.9) ,0.001
Diastolic blood pressure, mm Hg 2,005 90.1 (11.1) 3,851 87.2 (10.7) ,0.001
Forced expiratory volume, l/s 1,982 2.86 (0.86) 3,786 2.86 (0.86) 0.748
Blood-based factors Total serum cholesterol, mmol/l 2,007 6.87 (1.19) 3,866 6.41 (1.15) ,0.001
Serum triglycerides, mmol/l
a 1,897 1.16 (0.62) 3,625 1.03 (0.74) ,0.001
Fasting glucose, mmol/l 1,996 4.55 (0.85) 3,840 4.51 (0.68) 0.033
Serum uric acid, lmol/l 2,005 310 (72) 3,864 300 (70) ,0.001
C-reactive protein, mg/l
a 1,968 1.67 (5.22) 3,793 1.27 (5.01) ,0.001
Markers of renal function Serum creatinine, mg/dl 2,007 1.01 (0.25) 3,869 0.99 (0.50) 0.311
eGFRMDRD, ml/min/1.73 m
2 2,007 78.7 (15.3) 3,869 78.9 (14.5) 0.518
eGFRCG, ml/min/1.73 m
2 2,001 81.0 (16.8) 3,844 79.9 (16.2) 0.014
aValues were log-transformed for analysis and presented as geometric means (SD).
doi:10.1371/journal.pmed.0040270.t001
Table 2. Baseline Correlates of eGFRMDRD in Controls
Category Characteristic Quintile 1
( 90.7 ml/
min/1.73 m
2)
Quintile 2
(81.5–90.6 ml/
min/1.73 m
2)
Quintile 3
(74.6–81.4 ml/
min/1.73 m
2)
Quintile 4
(67.7–74.5 ml/
min/1.73 m
2)
Quintile 5
( 67.6 ml/
min/1.73 m
2)
t
a
No. of controls 773 774 774 774 774
Demographic
characteristics
Age, years 52.4 (7.2) 52.3 (8.3) 56.3 (9.1) 55.9 (8.4) 61.4 (9.0)  11.1***
Male sex, n (%) 620 (80.2) 687 (88.7) 453 (58.5) 521 (67.3) 383 (49.5) 15.2***
Established risk factors Current cigarette/pipe/cigar
smoker, n (%)
454 (58.7) 427 (55.2) 363 (46.3) 360 (46.5) 286 (37.0) 3.8**
Current cigarette smoker, n (%) 293 (37.9) 244 (31.5) 254 (32.8) 233 (30.1) 203 (26.2) 2.3*
BMI, kg/m
2 24.9 (3.6) 25.3 (3.5) 25.3 (4.0) 25.6 (3.5) 26.4 (4.0)  6.3***
Systolic blood pressure, mm Hg 137.4 (18.5) 139.5 (19.1) 142.4 (20.4) 141.9 (19.7) 145.6 (21.0)  2.0*
Diastolic blood pressure, mm Hg 86.0 (10.9) 87.5 (10.6) 86.8 (9.9) 88.2 (10.9) 87.6 (11.1)  3.9**
Forced expiratory volume in 1 s/l 3.0 (0.8) 3.1 (0.8) 2.8 (0.9) 2.9 (0.9) 2.5 (0.8)  5.6***
Lipids and metabolic
factors
Total serum cholesterol, mmol/l 6.3 (1.1) 6.3 (1.0) 6.5 (1.2) 6.5 (1.1) 6.6 (1.2)  5.4***
Log serum triglycerides, log
mmol/l
 0.072 (0.426)  0.006 (0.440) 0.015 (0.427) 0.041 (0.425) 0.158 (0.448)  7.2***
Log lipoprotein(a), log lmol/l 4.22 (1.61) 4.04 (1.76) 3.99 (1.74) 4.04 (1.73) 3.88 (1.8) 2.1*
Fasting glucose, mmol/l 4.6 (0.7) 4.5 (0.5) 4.5(0.7) 4.5 (0.8) 4.5 (0.7) 1.0
Inflammatory markers Log C-reactive protein, log mg/l 0.22 (1.18) 0.17 (1.11) 0.23 (1.10) 0.21 (1.11) 0.39 (1.09) 0.8
Log ESR, log mm/h 1.84 (0.94) 1.71 (0.95) 1.89 (0.95) 1.78 (1.00) 1.98 (0.98) 0.2
Log interleukin 6, log ng/l 0.67 (0.76) 0.61 (0.71) 0.71 (0.80) 0.63 (0.78) 0.68 (0.89) 0.5
Albumin, g/l 44.6 (3.5) 45.4 (4.7) 45.0 (4.0) 45.4 (5.1) 45.0 (4.6)  3.4**
Haemostatic and
rheological
Haemoglobin, g/l 14.6 (1.4) 14.9 (1.2) 14.4 (1.3) 14.6 (1.3) 14.4(1.3)  5.3***
variables Haematocrit, % 43.4 (7.0) 44.6 (5.0) 43.7 (3.8) 44.4 (3.9) 43.5 (5.0)  5.5***
Log vWF, log IU/dl 4.58 (0.42) 4.62 (0.41) 4.62 (0.41) 4.63 (0.41) 4.72 (0.41)  3.3*
Log TPA, log lg/l 2.42 (0.49) 2.48 (0.48) 2.48 (0.48) 2.54 (0.52) 2.59 (0.49)  4.9***
Log fibrin D-dimer, log lg/l 4.74 (1.01) 4.72 (1.02) 4.84 (0.98) 4.76 (0.99) 5.02 (0.97)  0.1
Renal markers Serum creatinine, mg/dl 0.82 (0.10) 0.96 (0.08) 0.95 (0.13) 1.05 (0.12) 1.18 (1.06)  24.0***
Serum uric acid, lmol/l 286 (63) 302 (63) 291 (68) 303 (69) 318 (80)  13.4***
Socioeconomic factor Nonmanual occupation, n (%) 242 (38.1) 271 (40.8) 235 (44.6) 233 (41.9) 215 (49.5)  3.3*
Values are means (SD) unless indicated otherwise.
at-Statistic from regression of eGFR on each of the characteristics adjusted for age, sex, period of recruitment, BMI, and smoking status.
ESR, erythrocyte sedimentation rate; TPA, tissue plasminogen activator; vWF, von Willebrand factor.
*p , 0.05; **p , 0.001; ***p , 0.0001.
doi:10.1371/journal.pmed.0040270.t002
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CHD risk in apparently healthy adults over most of the range
in renal function. A moderate association may, however, exist
among individuals with very low eGFR, i.e., those with eGFR
near or less than 60 ml/min/1.73 m
2 of body surface area. This
cut point coincides with the deﬁnition of CKD suggested by
the American National Kidney Foundation [25]. Such an
association implies a nonlinear effect of low eGFR on CHD
risk, a possibility that requires evaluation in larger numbers.
Moderate associations among individuals with eGFR near or
less than 60 ml/min/1.73 m
2 of body surface area were
consistently observed with CHD risk in many clinically
relevant subgroups, such as in women and men and at
different levels of established risk factors and other charac-
teristics (e.g., blood glucose levels and haematocrit). Our
updated meta-analysis reinforces the validity and general-
isability of the new data from the Reykjavik study; examina-
tion of several study characteristics in our review did not
Table 3. Relative Odds (95% CI) of CHD According to eGFRMDRD
Category Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5.1 Quintile 5.2 Quintile 5.3
eGFRMDRD, ml/min/1.73 m
2  90.7 81.5–90.6 74.6–81.4 67.7–74.5 64.5–67.8 59.4–64.4  59.3
Cases/controls, n 423/773 389/774 368/774 373/774 141/258 151/258 162/258
Adjusted for age, sex and period
a 1.00 (reference) 0.94 (0.79–1.12) 0.97 (0.81–1.16) 0.99 (0.83–1.19) 1.19 (0.93–1.53) 1.31 (1.03–1.68) 1.62 (1.26–2.09)
Adjusted for the preceding and
smoking status
1.00 (reference) 0.95 (0.80–1.13) 0.99 (0.83–1.19) 1.03 (0.86–1.23) 1.26 (0.98–1.62) 1.39 (1.08–1.78) 1.73 (1.34–2.23)
Adjusted for the preceding and
systolic blood pressure
1.00 (reference) 0.93 (0.78–1.11) 0.96 (0.80–1.15) 1.00 (0.84–1.20) 1.21 (0.94–1.56) 1.32 (1.03–1.69) 1.58 (1.22–2.04)
Adjusted for the preceding and total
cholesterol
1.00 (reference) 0.91 (0.76–1.08) 0.92 (0.76–1.11) 0.94 (0.78–1.13) 1.13 (0.87–1.46) 1.21 (0.94–1.56) 1.44 (1.10–1.87)
Adjusted for the preceding and other
established risk factors
b
1.00 (reference) 0.88 (0.73–1.07) 0.88 (0.73–1.07) 0.89 (0.74–1.08) 1.03 (0.79–1.35) 1.12 (0.86–1.46) 1.33 (1.01–1.75)
After further adjustment for C-reactive protein, the ORs (95% CIs) compared to the first quintile were: eGFRMDRD quintile 2: 0.89 (0.74–1.08); quintile 3: 0.89 (0.74–1.09); quintile 4: 0.91
(0.75–1.10); quintile 5.1: 1.07 (0.81–1.40); quintile 5.2: 1.14 (0.87–1.49); quintile 5.3: 1.37 (1.04–1.81). Using the Kidney Disease Outcomes Quality Initiative classification, the ORs (95% CIs),
compared to individuals with a eGFR   90 ml/min/1.73 m
2, were, for eGFR 60–89 ml/min/1.73 m
2, 0.90 (0.78–1.05); for eGFR , 60 ml/min/1.73 m
2, 1.25 (0.96–1.63).
a‘‘Period’’ refers to calendar year of recruitment.
bEstablished risk factors included triglycerides (log transformed) and BMI.
doi:10.1371/journal.pmed.0040270.t003
Figure 2. Association between Estimated Baseline GFR and CHD Adjusted for Age, Sex, Period, Smoking Status, and Other Established Risk Factors
eGFR was calculated using Modification of Diet in Renal Disease equation. The size of the data markers is proportional to the inverse of the variance of
the ORs. 95% CIs are calculated using floating-variance. Established risk factors included total cholesterol, triglycerides (log transformed), systolic blood
pressure, and BMI. eGFRMDRD, overall v
2 with 6 df ¼ 14.6, p ¼ 0.02.
doi:10.1371/journal.pmed.0040270.g002
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Renal Function and Coronary Heart Diseaseidentify important sources of heterogeneity. Finally, our data
demonstrate that the decade-to-decade consistency in renal
function in apparently healthy adults is similar to that for
blood pressure or total blood cholesterol, although larger
assessments will be required to assess whether this variability
differs importantly at different levels of renal function.
These ﬁndings from the Reykjavik study may have several
implications. First, the apparent lack of any association of
renal function in the normal range with CHD risk implies
that strategies which aim to shift the population distribution
of renal function may not be optimum for the purposes of
CHD prevention [30]. By contrast, suggestions of associations
of lower-than-normal eGFR with CHD risk encourage further
investigation of targeting existing cardioprotective interven-
tions (such as lipid- and blood pressure-lowering agents
[6,31–33]) in the 5%–10% of the general western adult
population who fulﬁl the criteria for CKD [34]. Second, highly
signiﬁcant associations of low eGFR with tissue plasminogen
activator antigen that have been observed stimulate interest
in the potential relevance of haemostasis to renal function
[35], whereas there were no strong cross-sectional associa-
tions of low eGFR with C-reactive protein, interleukin 6, and
lipoprotein(a) [36,37]. Third, our data highlight the need for
studies that can determine whether eGFR is primarily a risk
factor for CHD or mainly a marker of subclinical cardiovas-
cular diseases (i.e., reﬂecting the extent and severity of
atherosclerosis in renal and other vascular beds such as the
coronary circulation [10,38]). The former possibility has been
highlighted in previous reports of signiﬁcant correlations
between coronary and renal arteriosclerosis in the absence of
any overt clinical CKD or CHD [39,40]. The latter possibility
is suggested by the modest residual association observed
between low eGFR and CHD risk after adjustment for
measured levels of established risk factors, as adjustment for
the full impact of these risk factors might have reduced the
association still further (or even abolished it).
The strengths and potential limitations of the present study
merit careful consideration. Our report involves new data on
eGFR levels and incident CHD that almost double the
available evidence on major CHD outcomes in population-
Figure 3. Meta-analysis of Reported Data from Prospective Studies in Essentially General Western Populations of CHD Risk in Individuals with eGFRMDRD
of ,60 versus   60 ml/min/1.73 m
2, with Adjustments Reported for Several Established Cardiovascular Risk Factors
The size of the data markers is proportional to the inverse of the variance of the risk ratios. Overall estimate calculated using fixed effect meta-analysis.
Random effects overall relative risk 1.32, 95% CI 1.19–1.47. Test for heterogeneity: v
2 ¼ 12.9 with 6 df, p ¼ 0.045; I
2 ¼ 56% (95% CI 0%–80%). For
adjustments see Table 3. KORA, The MONICA/KORA Augsberg Study; NHANES, National Health and Nutrition Examination Survey.
doi:10.1371/journal.pmed.0040270.g003
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Renal Function and Coronary Heart Diseasebased studies and avoids the potentially misleading analysis of
heterogeneous cardiovascular disease outcomes used in some
studies. We identiﬁed participants in population registers,
had high response and follow-up rates, used robust methods
to ascertain CHD outcomes, and minimized potential biases
by exclusion of participants with prevalent diabetes, CHD,
and stroke. Concomitant measurements of several established
risk factors and emerging markers in the same participants
enabled adjustment for a range of possible confounding
factors. Although our assays produced creatinine values
comparable with those in earlier studies (Table 4), eGFR
might not be optimal for use in general populations, because
standard prediction equations used to calculate it have been
developed in patients with kidney disease [21,41,42]. Fur-
thermore, serum creatinine is, of course, an imperfect
indicator of GFR because it is inﬂuenced by creatinine
generation and tubular secretion, but the eGFR equations
employed in the current analyses are in widespread use and
take into account age, sex, and weight (the latter only in the
Cockcroft-Gault equation). Future studies may improve on
eGFR methods by recalibration of serum creatinine assays to
the isotope-dilution mass spectrometry standard [43,44] and
by measurement of potentially more sensitive markers such as
serum cystatin C [45] or symmetric and asymmetric dimethy-
larginine (SDMA and ADMA) [46, 47]. The current analyses
do not address low eGFR and CHD risk among ethnic groups
who may be particularly susceptible to the effects of impaired
renal function [48].
Conclusion
Our new large-scale data in apparently healthy Western
adults—reinforced by a meta-analysis of previous relevant
studies in similar populations (i.e., Western European, North
American, or Australian)—suggest that levels of eGFR
compatible with the deﬁnition of CKD are associated with
about a 40% increased risk in subsequent CHD. These
ﬁndings could have implications for further understanding
the pathogenesis of CHD and targeting existing cardiopro-
tective interventions.
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Background. Coronary heart disease (CHD), the leading cause of death
in most Western countries, is a ‘‘cardiovascular’’ disease—literally a
disorder affecting the heart and/or blood vessels. In CHD, the blood
vessels that supply the heart become increasingly narrow. Eventually, the
flow of blood to the heart slows or stops, causing chest pains (angina),
breathlessness, and heart attacks. Many factors increase the risk of
developing CHD and other cardiovascular diseases, including high blood
pressure, high blood levels of cholesterol (a type of fat), or being
overweight. Individuals can reduce their chances of developing
cardiovascular disease by taking drugs to reduce their blood pressure
or cholesterol levels or by making lifestyle changes (so-called cardio-
protective interventions). Another important risk factor for cardiovascular
disease is end-stage chronic kidney disease (CKD), a condition in which
the kidneys stop working. (In healthy people, the kidneys remove waste
products and excess fluid from the body.) People with end-stage CKD
(which is treated by dialysis) have about a five times higher risk of dying
from cardiovascular disease compared with healthy people.
Why Was This Study Done? End-stage CKD is preceded by a gradual
loss of kidney function. There is a clear association between non-dialysis–
dependent CKD and the incidence of cardiovascular events (such as
heart attacks) in people who already have signs of cardiovascular
disease. But are people with slightly dysfunctional kidneys (often
because of increasing age) but without any obvious cardiovascular
disease at greater risk of developing cardiovascular diseases than people
with fully functional kidneys? If the answer is yes, it might be possible to
reduce CHD deaths by minimizing the exposure of people with CKD to
other risk factors for cardiovascular disease. In this study, the researchers
have taken two approaches to answer this question. In a population-
based study, they have examined whether there is any association in
healthy adults between kidney function measured at the start of the
study and incident CHD (the first occurrence of CHD) over subsequent
years. In addition, they have systematically searched the published
literature for similar studies and combined the results of these studies
using statistical methods, a so-called ‘‘meta-analysis.’’
What Did the Researchers Do and Find? Between 1967 and 1991,
nearly 19,000 middle-aged men and women without a history of heart
attacks living in Reykjavik, Iceland, enrolled in a prospective study of
cardiovascular disease. Baseline blood samples were taken at enrollment
and the participants’ health monitored for 20 years on average. The
researchers identified 2,007 participants who suffered a nonfatal heart
attack or died of CHD during follow-up and 3,869 who remained disease
free. They then calculated the estimated glomerular filtration rate (eGFR;
a measure of kidney function) for each participant from baseline
creatinine measurements (creatinine is a muscle waste product). There
was no association between lower-than-average eGFRs and the risk of
developing CHD over most of the range of eGFR values. However,
people whose eGFR was below approximately 60 units had about a 40%
higher risk of developing CHD after allowing for established cardiovas-
cular risk factors than individuals with higher eGFRs. This finding was
confirmed by the meta-analysis of six previous studies, which included a
further 2,700 incident CHD cases.
What Do These Findings Mean? These findings indicate that people
with an eGFR below about 60 units (the cut-off used to define CKD) may
have an increased risk of developing CHD. They also indicate a nonliner
association between kidney function and CHD risk. That is, any
association with CHD became evident only when the eGFR dropped
below about 60 units. These findings need confirming in different ethnic
groups and by using more accurate methods to measure eGFRs.
Nevertheless, they suggest that improving kidney function across the
board is unlikely to have much effect on the overall incidence of CHD.
Instead, they suggest that targeting cardioprotective interventions at the
one in ten adults in Western countries whose eGFR is below 60 units
might be a good way to reduce the burden of CHD.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040270.
  MedlinePlus encyclopedia pages on coronary heart disease, chronic
kidney failure, and end-stage kidney disease (in English and Spanish).
  Information for patients and carers from the American Heart
Association on all aspects of heart disease, including prevention of
CHD
  Information from the British Heart Foundation on heart disease and on
keeping the heart healthy
  Information on chronic kidney disease from the US National Kidney
Foundation, and the US National Kidney and Urologic Diseases
Information Clearing House (in English and Spanish)
  Information on chronic kidney disease from the UK National Kidney
Foundation
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